Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 36

References for PMC Articles for PubMed (Select 19289842)

1.

EGFR family: structure physiology signalling and therapeutic targets.

Burgess AW.

Growth Factors. 2008 Oct;26(5):263-74. doi: 10.1080/08977190802312844. Review.

PMID:
18800267
2.

Rash from EGFR inhibitors: opportunities and challenges for palliation.

Solomon BM, Jatoi A.

Curr Oncol Rep. 2008 Jul;10(4):304-8. Review.

PMID:
18778556
3.

Structure-based view of epidermal growth factor receptor regulation.

Ferguson KM.

Annu Rev Biophys. 2008;37:353-73. doi: 10.1146/annurev.biophys.37.032807.125829. Review.

4.

EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality.

Milano G, Spano JP, Leyland-Jones B.

Br J Cancer. 2008 Jul 8;99(1):1-5. doi: 10.1038/sj.bjc.6604373. Epub 2008 May 27. Review.

5.

Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.

Schmiedel J, Blaukat A, Li S, Knöchel T, Ferguson KM.

Cancer Cell. 2008 Apr;13(4):365-73. doi: 10.1016/j.ccr.2008.02.019.

6.

Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8.

Li S, Kussie P, Ferguson KM.

Structure. 2008 Feb;16(2):216-27. doi: 10.1016/j.str.2007.11.009.

7.

A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors.

Scott AM, Lee FT, Tebbutt N, Herbertson R, Gill SS, Liu Z, Skrinos E, Murone C, Saunder TH, Chappell B, Papenfuss AT, Poon AM, Hopkins W, Smyth FE, MacGregor D, Cher LM, Jungbluth AA, Ritter G, Brechbiel MW, Murphy R, Burgess AW, Hoffman EW, Johns TG, Old LJ.

Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4071-6. Epub 2007 Feb 28. Erratum in: Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15965. Ritter, Gerd [added].

8.

Epidermal growth factor receptor targeting in cancer.

Mendelsohn J, Baselga J.

Semin Oncol. 2006 Aug;33(4):369-85. Review.

PMID:
16890793
9.

Nondermatologic adverse events associated with anti-EGFR therapy.

Sandler AB.

Oncology (Williston Park). 2006 Apr;20(5 Suppl 2):35-40. Review.

10.

Structural model of the mAb 806-EGFR complex using computational docking followed by computational and experimental mutagenesis.

Sivasubramanian A, Chao G, Pressler HM, Wittrup KD, Gray JJ.

Structure. 2006 Mar;14(3):401-14.

11.

An automated peptide and protein thiazolidine coupling chemistry for biosensor immobilization giving a unique N-terminal orientation.

Wade JD, Hojo K, Kawasaki K, Johns TG, Catimel B, Rothacker J, Nice EC.

Anal Biochem. 2006 Jan 15;348(2):315-7. Epub 2005 Sep 26. No abstract available.

PMID:
16310754
12.

Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.

Perera RM, Narita Y, Furnari FB, Gan HK, Murone C, Ahlkvist M, Luwor RB, Burgess AW, Stockert E, Jungbluth AA, Old LJ, Cavenee WK, Scott AM, Johns TG.

Clin Cancer Res. 2005 Sep 1;11(17):6390-9.

13.

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.

Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM.

Cancer Cell. 2005 Apr;7(4):301-11.

14.

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.

Baselga J, Arteaga CL.

J Clin Oncol. 2005 Apr 10;23(11):2445-59. Epub 2005 Mar 7. Review. Erratum in: J Clin Oncol. 2005 Sep 1;23(25):6281.

PMID:
15753456
15.

Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display.

Chao G, Cochran JR, Wittrup KD.

J Mol Biol. 2004 Sep 10;342(2):539-50. Erratum in: J Mol Biol. 2005 Mar 11;346(5):1455.

PMID:
15327953
16.

Refinement of macromolecular structures by the maximum-likelihood method.

Murshudov GN, Vagin AA, Dodson EJ.

Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55.

PMID:
15299926
17.

Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor.

Johns TG, Adams TE, Cochran JR, Hall NE, Hoyne PA, Olsen MJ, Kim YS, Rothacker J, Nice EC, Walker F, Ritter G, Jungbluth AA, Old LJ, Ward CW, Burgess AW, Wittrup KD, Scott AM.

J Biol Chem. 2004 Jul 16;279(29):30375-84. Epub 2004 Apr 9.

18.

CR1/CR2 interactions modulate the functions of the cell surface epidermal growth factor receptor.

Walker F, Orchard SG, Jorissen RN, Hall NE, Zhang HH, Hoyne PA, Adams TE, Johns TG, Ward C, Garrett TP, Zhu HJ, Nerrie M, Scott AM, Nice EC, Burgess AW.

J Biol Chem. 2004 May 21;279(21):22387-98. Epub 2004 Mar 11.

19.

Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478.

Johns TG, Luwor RB, Murone C, Walker F, Weinstock J, Vitali AA, Perera RM, Jungbluth AA, Stockert E, Old LJ, Nice EC, Burgess AW, Scott AM.

Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15871-6. Epub 2003 Dec 15.

20.

An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors.

Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S.

Mol Cell. 2003 Sep;12(3):541-52. Review.

PMID:
14527402
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk